EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

ENCell Co., Ltd (456070) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of ENCell Co., Ltd KRW 1,763, price KRW 5,920, upside -70.2%, quality 26 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

EC Thin data Sep 24, 2026

ENCell Co., Ltd

456070 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 1,763 KRW · Strongly overvalued (−70%)
!Quality 26/100
!Weak Growth (revenue 3y −10.6 %/yr)
!Low debt · negative free cash flow
!Trails peers (1/7)
!Narrow moat 12/100
!Evidence only low, so the estimate is less certain
Watch ENCell Co., Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

38,250 KRW 4,905 KRW Fair Value 1,763 KRW Aug 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

25‑month range 4,905 KRW – 38,250 KRW · fair‑value band 1,163 KRW – 2,203 KRW · the 5,920 KRW price screens above the 1,763 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow ENCell Co. in your weekly email

Every Wednesday you see whether ENCell Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease. It also provides contracting development and manufacturing services for biopharmaceutical products.

Show more

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease. It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea.

Stock analysis

ENCell Co., Ltd (456070) currently trades at 5,920 KRW, while our model-based Fair Value estimate is 1,763 KRW, implying the stock looks roughly 235.8% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 1,163 KRW (bear) to 2,203 KRW (bull), the price of 5,920 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

ENCell Co., Ltd reported revenue of 5.3B KRW in FY2025 versus 3.9B KRW in FY2021, a compound +7.7%/yr. Reported net income was −16.1B KRW in FY2025.

Key figures

Market cap 64.5B KRW (≈ $47.4M) · P/S ratio 14.9 · Return on equity −42.4% · Return on assets (EBIT) −21.3% · Operating margin −1,576% · Revenue (TTM) 4.5B KRW · Revenue growth (YoY) −71.8% · Free cash flow −13.3B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 71% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −70%, 456070 screens richer than that median.

Fair Value models

Bear 1,163 KRW Fair Value 1,763 KRW Bull 2,203 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 1,791 KRW 2,400 KRW 3,582 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 1,791 KRW 2,400 KRW 3,582 KRW 54

Open the full fair value analysis →

Notify me when 456070 reaches fair value

Put 456070 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 26/100

Of which business quality 29 · Market factors (momentum, volatility) 4

Profitability 0
Margins and returns on capital today
Quality Growth 26
Are margins and returns improving?
Cashflow 3
Earnings quality: real cash, not paper profit
Fin. Strength 71
Balance sheet, leverage, solvency risk
Investment 37
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 6
Price trend over the last 3–12 months (market factor)
52W Momentum 3
Distance to the 52-week high (market factor)
Net Issuance 48
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−27.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−64.5% (2021) → −339.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

456070 screens 236% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare ENCell Co., Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −70% · Below median
Profitability
Return on assets −20% · Below median
Growth and dividend
Revenue growth −72% · Bottom 25%
Balance sheet
Debt / equity 0.23× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (TTM) 0.01× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)89 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

ENCell Co., Ltd · Fair Value
1,763 KRW −236%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "ENCell Co., Ltd Fair Value". https://www.fairvalue-calculator.com/stock/456070

Frequently asked questions

Is ENCell Co., Ltd (456070) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,763 KRW versus a price of 5,920 KRW, about −70% upside (overvalued).
What is the fair value of 456070?
Our model-based fair value for ENCell Co., Ltd is 1,763 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 5,920 KRW.
What is the quality score of 456070?
ENCell Co., Ltd has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ENCell Co., Ltd (456070)?
Our model-based price target is the fair value of 1,763 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 1,163 KRW, optimistic scenario 2,203 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ENCell Co., Ltd stock forecast for 2026?
Our models put fair value at 1,763 KRW, about −70% upside versus a price of 5,920 KRW (overvalued). Cautious scenario 1,163 KRW, optimistic scenario 2,203 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ENCell Co., Ltd (456070)?
ENCell Co., Ltd reported trailing-twelve-month revenue of about 4.5B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of ENCell Co., Ltd (456070)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ENCell Co., Ltd it is 1,763 KRW per share (as of Sep 24, 2026), against a price of 5,920 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is ENCell Co., Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 456070 trades above its calculated fair value: price 5,920 KRW, fair value 1,763 KRW, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 456070?
No. The price is what the market pays today (5,920 KRW); the fair value is what the company's own numbers justify (1,763 KRW). For ENCell Co., Ltd the two are 4,157 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ENCell Co., Ltd worth?
The market values ENCell Co., Ltd at about 64.5B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 5,920 KRW; our models calculate a fair value of 1,763 KRW per share.
What do the bullish and bearish scenarios say about 456070?
Our models span a range for ENCell Co., Ltd: cautious scenario 1,163 KRW, base 1,763 KRW, optimistic 2,203 KRW per share (as of Sep 24, 2026, price 5,920 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of ENCell Co., Ltd (456070)?
Balance-sheet figures for ENCell Co., Ltd (as of Sep 24, 2026): return on equity −42.4%, debt of 0.23 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 456070 from its 52-week high?
ENCell Co., Ltd trades at 5,920 KRW, about 71% below its 52-week high of 20,150 KRW and 21% above the low of 4,905 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,763 KRW is for.
Which stocks are comparable to ENCell Co., Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ENCell Co., Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 5,920 KRW, calculated fair value 1,763 KRW (−70%), Quality Score 26/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 456070 calculated?
We run ENCell Co., Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,763 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. ENCell Co., Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ENCell Co., Ltd (456070)?
The closing price on Sep 23, 2026 was 5,920 KRW. Our model-based fair value is 1,763 KRW, about −70% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ENCell Co., Ltd right now?
The price sits above even our optimistic bull case (2,203 KRW). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1,163 KRW to 2,203 KRW) leaves room in how you read the outcome.

Key figures of ENCell Co., Ltd

How large is the market capitalisation of ENCell Co., Ltd (456070)?
The market capitalisation of ENCell Co., Ltd is 64.5B KRW (≈ $47.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ENCell Co., Ltd (456070)?
The price-to-sales ratio of ENCell Co., Ltd is 14.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of ENCell Co., Ltd (456070)?
The return on equity (ROE) of ENCell Co., Ltd is −42.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ENCell Co., Ltd (456070)?
On an EBIT basis the return on assets of ENCell Co., Ltd is −21.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ENCell Co., Ltd (456070)?
The operating margin of ENCell Co., Ltd is −1,576% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ENCell Co., Ltd (456070)?
Revenue at ENCell Co., Ltd is growing −71.8% versus a year earlier (3y avg −10.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ENCell Co., Ltd (456070) generate?
The free cash flow of ENCell Co., Ltd is −13.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch ENCell Co., Ltd in the live analysis

One click puts ENCell Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.